Redeye comments on Isofol’s announcement of the outcome of its TO1 warrant exercise. We note a high subscription rate of approximately 93.6%, with additional support from Solasia Pharma through guarantee commitments, resulting in total proceeds of around SEK18.9m before costs. Overall, we view the outcome as positive and in line with expectations, providing incremental funding while confirming continued support from shareholders.
LÄS MER
